Form 4: Royalty Pharma CFO Sells Shares Under 10b5-1 Plan

Royalty Pharma plc's EVP & CFO, Terrance P. Coyne, reported the sale of Class A Ordinary Shares valued at approximately $48.33 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, reported transactions involving Class A Ordinary Shares.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on August 8, 2025.
• A total of 1,875 shares were sold at a weighted average price of $48.33, with individual sales ranging from $48.07 to $48.67.
• Following these sales, Coyne beneficially owns 42,011 shares directly and indirectly through various entities and his spouse.
• The filing also notes additional holdings in limited partnership interests and Class E Ordinary Shares subject to vesting conditions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider selling, despite the use of a 10b5-1 plan. The lack of specific details on the total number of shares sold relative to holdings prevents a more definitive assessment.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading related sales.
• The weighted average sale price of $48.33 suggests a stable market price during the transaction period.

Negatives

• The sale of a significant number of shares by a key executive could be perceived negatively by the market.
• The total number of shares sold is not explicitly stated as a percentage of the executive's total holdings or outstanding shares, making it difficult to assess the magnitude of the sale.

Risks

• Potential for negative market perception due to insider selling, even if conducted under a 10b5-1 plan.
• The value of Class E Ordinary Shares is subject to vesting conditions, introducing uncertainty regarding their ultimate realization.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• "All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025."
• "The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.07 to $48.67 per share."
• "The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event for executives in the pharmaceutical and biotechnology sectors, often related to personal financial planning rather than a negative view of the company's prospects. However, the volume and frequency of such sales are closely monitored by investors.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal of reduced confidence by a key executive, potentially impacting share price in the short term.
• Employees: May observe the sale, but direct impact is minimal unless they hold company stock.
• Creditors: No direct impact from this type of filing.
• Suppliers: No direct impact from this type of filing.

Next Steps

• The reporting person may continue to execute transactions under the existing 10b5-1 plan.
• The company may provide further information upon written request from the SEC, security holders, or the issuer regarding the specific sale prices.

Key Dates

Recommendation

The filing reports routine share sales by an executive under a pre-established 10b5-1 plan. While insider selling can be a negative signal, the structured nature of the plan suggests it's not necessarily a reflection of immediate negative company outlook. Without further context on the volume of shares sold relative to total holdings or other significant company news, a 'hold' recommendation is prudent, advising investors to monitor future filings and company performance.

Keywords

Royalty Pharma, RPRX, Form 4, Insider Trading, 10b5-1 Plan, Terrance P. Coyne, Share Sale, Class A Ordinary Shares, EVP & CFO